SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥147.16+CN¥4.27 (+2.99%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
Loading market information…
HKSE · 2126.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
JW (Cayman) Therapeutics Co. Ltd’s quoted price sits in the lower half of its reported 52-week range, 46.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
JW (Cayman) Therapeutics Co. Ltd’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow JW (Cayman) Therapeutics Co. Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 29, 2023 | -HK$1.01-9.41% vs estimate | HK$94.82M-46.54% vs estimate |
|---|
| Q4 2022 | Mar 29, 2023 | -HK$1.14-1.0% vs estimate | HK$90.39M-1.6% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥147.16+CN¥4.27 (+2.99%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
CN¥49.23+CN¥0.61 (+1.25%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.03% below the high.
HK$51.90+HK$1.25 (+2.47%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.64% below the high.
CN¥181.46+CN¥2.46 (+1.37%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.38% below the high.
HK$33.16+HK$0.08 (+0.24%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 24.83% below the high.
HK$45.60+HK$0.54 (+1.2%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.07% below the high.
HK$11.01+HK$0.06 (+0.55%)
CARsgen Therapeutics Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 61.5% below the high.
HK$0.36HK$0.00 (0.0%)
Immunotech Biopharm Ltd’s quoted price sits in the lower half of its reported 52-week range, 90.46% below the high.
